Howland Capital Management LLC lifted its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 60.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,069 shares of the medical research company’s stock after purchasing an additional 1,154 shares during the period. Howland Capital Management LLC’s holdings in Amgen were worth $594,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. CWM LLC raised its position in Amgen by 11.1% in the third quarter. CWM LLC now owns 3,635 shares of the medical research company’s stock worth $703,000 after acquiring an additional 364 shares during the period. Portland Global Advisors LLC raised its position in Amgen by 0.4% in the third quarter. Portland Global Advisors LLC now owns 18,267 shares of the medical research company’s stock worth $3,535,000 after acquiring an additional 75 shares during the period. Arcadia Investment Management Corp MI raised its position in Amgen by 1,126.2% in the third quarter. Arcadia Investment Management Corp MI now owns 2,575 shares of the medical research company’s stock worth $498,000 after acquiring an additional 2,365 shares during the period. Bellecapital International Ltd. raised its position in Amgen by 62.9% in the third quarter. Bellecapital International Ltd. now owns 2,165 shares of the medical research company’s stock worth $419,000 after acquiring an additional 836 shares during the period. Finally, Kwmg LLC bought a new stake in Amgen in the third quarter worth about $1,979,000. 76.33% of the stock is currently owned by institutional investors.
Shares of NASDAQ:AMGN opened at $202.30 on Thursday. The company has a 50 day moving average of $198.98 and a 200 day moving average of $187.08. The stock has a market cap of $122.84 billion, a P/E ratio of 14.05, a P/E/G ratio of 2.71 and a beta of 1.11. Amgen, Inc. has a 12 month low of $166.30 and a 12 month high of $211.90. The company has a current ratio of 2.89, a quick ratio of 2.60 and a debt-to-equity ratio of 2.58.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 6th. Investors of record on Friday, November 15th will be paid a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a yield of 2.87%. Amgen’s dividend payout ratio is currently 40.28%.
In other Amgen news, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total value of $77,792.00. Following the completion of the transaction, the director now owns 16,336 shares of the company’s stock, valued at approximately $2,990,141.44. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $206.70, for a total transaction of $413,400.00. Following the completion of the transaction, the director now directly owns 16,336 shares of the company’s stock, valued at approximately $3,376,651.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 17,851 shares of company stock valued at $3,671,900. 0.25% of the stock is owned by corporate insiders.
Several brokerages have commented on AMGN. Piper Jaffray Companies lifted their price objective on shares of Amgen from $210.00 to $218.00 and gave the stock an “overweight” rating in a research report on Monday, August 26th. Bank of America began coverage on shares of Amgen in a research report on Wednesday, October 16th. They issued a “neutral” rating and a $215.00 price objective on the stock. Credit Suisse Group reaffirmed an “outperform” rating and issued a $225.00 price objective (up previously from $202.00) on shares of Amgen in a research report on Friday, August 16th. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Amgen in a research report on Monday, September 30th. Finally, Citigroup reaffirmed a “buy” rating on shares of Amgen in a research report on Monday, August 12th. Eleven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Amgen currently has an average rating of “Buy” and a consensus target price of $217.28.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.